Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AgomAb Therapeutics
Biotech
Why biotech IPOs are back for 2026
Whisper it, but we may finally be seeing the IPO window reopening in 2026.
James Waldron
Feb 13, 2026 3:30am
Agomab, SpyGlass head to Nasdaq with IPOs totaling $350M
Feb 6, 2026 4:04am
Belgium biotech Agomab seeks $212M Nasdaq debut
Jan 29, 2026 10:13am
Immunology biotech Agomab, eye-focused SpyGlass share IPO plans
Jan 19, 2026 4:50am
Agomab's ALK5 inhibitor hits intestinal target in Crohn's trial
Mar 10, 2025 8:50am
Agomab uses $100M series C to push Crohn's drug through phase 2
Oct 11, 2023 8:50am
